本文選題：輕鏈淀粉樣變性　切入點(diǎn)：來那度胺　出處：《腎臟病與透析腎移植雜志》2017年03期 　論文類型：期刊論文

【摘要】：目的:觀察來那度胺聯(lián)合地塞米松(LD)治療復(fù)發(fā)難治性輕鏈淀粉樣變性(AL型)的臨床療效及安全性。方法:收集2012年12月至2015年11月在南京總醫(yī)院國家腎臟疾病臨床醫(yī)學(xué)研究中心接受LD治療的復(fù)發(fā)難治性AL淀粉樣變性患者的臨床資料�；仡櫺苑治鲅簩W(xué)、器官反應(yīng)情況及不良反應(yīng)。結(jié)果:共10例患者納入研究,其中男性7例、女性3例,中位年齡為64.5(56.8,68.8)歲。7例患者納入療效分析,3例患者獲得血液學(xué)應(yīng),其中1例獲得完全緩解。7例患者均未獲得腎臟反應(yīng),2例獲得心臟反應(yīng)。所有患者均存活,無血液學(xué)進(jìn)展,2例心臟進(jìn)展,1例進(jìn)入終末期腎病。無一例發(fā)生血液學(xué)進(jìn)展。3/4級(jí)不良反應(yīng)發(fā)生率30%。結(jié)論:LD方案作為復(fù)發(fā)難治性AL淀粉樣變性患者的挽救治療有一定的療效且安全性較高,嚴(yán)重不良反應(yīng)發(fā)生率較低。
[Abstract]:Objective: to observe the clinical efficacy and safety of renalidomide combined with dexamethasone (LDX) in the treatment of refractory refractory amyloidosis (AL). Methods: from December 2012 to November 2015, the National Renal Disease of Nanjing General Hospital was collected. Clinical data of patients with recurrent refractory AL amyloidosis treated with LD. Retrospective analysis of hematology. Results: a total of 10 patients were included in the study, including 7 males and 3 females, with a median age of 64.5 / 56.8 / 68.8). One of the 7 patients with complete remission had no renal response and 2 had cardiac response. All the patients survived. No hematological progress was found in 2 patients with cardiac progression and 1 patient entered end-stage nephropathy. No hematological progression. 3 / 4 grade adverse reaction rate was 30%. Conclusion the fraction LD regimen is a salvage therapy for refractory AL amyloidosis. Has high efficacy and safety. The incidence of severe adverse reactions was lower.
【作者單位】： 南京軍區(qū)南京總醫(yī)院腎臟科國家腎臟疾病臨床醫(yī)學(xué)研究中心全軍腎臟病研究所;
【基金】：國家科技支撐計(jì)劃項(xiàng)目課題(2015BAI09B05,2015BAI12B02) 江蘇省青年醫(yī)學(xué)人才計(jì)劃(QNRC2016895) 國家“精準(zhǔn)醫(yī)學(xué)”重點(diǎn)研發(fā)計(jì)劃項(xiàng)目(2016YFC0904100)
【分類號(hào)】：R597.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前4條

1 胡e，

本文編號(hào)：1578429